Regeneron Pharmaceuticals Inc $ 305.43 -0.01 (0%)
On watch
Volume:
142,510
Avg Vol (1m):
692,756
Market Cap $:
33.42 Bil
Enterprise Value $:
31.46 Bil
P/E (TTM):
16.91
P/B:
3.58
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
| Graham Number | ||
| Peter Lynch Value | ||
|
Price: $305.43 | ||
Manual of Stocks™ Web
Financial Strength | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 3.75 | ||
| Equity-to-Asset | 0.74 | ||
| Debt-to-Equity | 0.07 | ||
| Debt-to-EBITDA | 0.31 | ||
| Interest Coverage | 70.08 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 8.05 | ||
| Beneish M-Score | -2.31 | ||
| WACC vs ROIC | |||
Profitability | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 29.58 | ||
| Net Margin % | 28.59 | ||
| ROE % | 24.05 | ||
| ROA % | 17.68 | ||
| ROC (Joel Greenblatt) % | 45.14 | ||
| 3-Year Revenue Growth Rate | 18 | ||
| 3-Year EBITDA Growth Rate | 27.8 | ||
| 3-Year EPS without NRI Growth Rate | 56.8 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 16.91 | ||
| Forward PE Ratio | 12.36 | ||
| PE Ratio without NRI | 16.91 | ||
| Price-to-Owner-Earnings | 27.12 | ||
| PB Ratio | 3.58 | ||
| PS Ratio | 4.83 | ||
| Price-to-Free-Cash-Flow | 18.37 | ||
| Price-to-Operating-Cash-Flow | 15.44 | ||
| EV-to-EBIT | 14.89 | ||
| EV-to-EBITDA | 13.71 | ||
| EV-to-Revenue | 4.35 | ||
| PEG Ratio | 0.58 | ||
| Shiller PE Ratio | 48.67 | ||
| Current Ratio | 3.88 | ||
| Quick Ratio | 3.11 | ||
| Days Inventory | 736.92 | ||
| Days Sales Outstanding | 123.87 | ||
| Days Payable | 159.25 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.58 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 1.52 | ||
| Price-to-Median-PS-Value | 0.49 | ||
| Price-to-Peter-Lynch-Fair-Value | 0.68 | ||
| Price-to-Graham-Number | 1.64 | ||
| Earnings Yield (Greenblatt) % | 6.72 | ||
| Forward Rate of Return (Yacktman) % | 23.14 |